Multidisciplinary Cutaneous Lymphoma Group


The publication page is designed to update our visitors on selected publications from our cutaneous lymphoma group. This information can serve as a general reference guide on cutaneous lymphomas and to learn about our selected research activities.

These papers are available through online reference libraries or Stanford’s Lane Medical Library resources.


Topical Chemotherapy in Cutaneous T-cell Lymphoma: Positive Results of a Randomized, Controlled, Multicenter Trial Testing the Efficacy and Safety of a Novel Mechlorethamine, 0.02%, Gel in Mycosis Fungoides. Lessin SR, Duvic M, Guitart J, Pandya AG, Strober BE, Olsen EA, Hull CM, Knobler EH, Rook AH, Kim EJ, Naylor MF, Adelson DM, Kimball AB, Wood GS, Sundram U, Wu H, Kim YH. Arch Dermatol 149:25-32, 2013.


Cutaneous γδ T-cell lymphomas: a spectrum of presentations with overlap with other cytotoxic lymphomas. Guitart J, Weisenburger DD, Subtil A, Kim E, Wood G, Duvic M, Olsen E, Junkins-Hopkins J, Rosen S, Sundram U, Ivan D, Selim MA, Pincus L, Deonizio JM, Kwasny M, Kim YH. Am J Surg Pathol 36:1656-65, 2012.


Transcriptome sequencing in Sezary syndrome identifies Sezary cell and mycosis fungoides-associated lncRNAs and novel transcripts. Lee CS, Ungewickell A, Bhaduri A, Qu K, Webster DE, Armstrong R, Weng WK, Aros CJ, Mah A, Chen RO, Lin M, Sundram U, Chang HY, Kretz M, Kim YH, Khavari PA. Blood 120:3288-97, 2012.


Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma. Horwitz SM, Kim YH, Foss F, Zain JM, Myskowski PL, Lechowicz MJ, Fisher DC, Shustov AR, Bartlett NL, Delioukina ML, Koutsoukos T, Saunders ME, O'Connor OA, Duvic M. Blood 119:4115-22, 2012.

  In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase I/II study.
Kim YH, Gratzinger D, Harrison C, Brody JD, Czerwinski DK, Ai WZ, Morales A, Abdulla F, Xing L, Navi D, Tibshirani RJ, Advani RH, Lingala B, Shah S, Hoppe RT, Levy R. Blood. 2011
  Bexarotene Is Active Against Subcutaneous Panniculitis-Like T-Cell Lymphoma in Adult and Pediatric Populations.
Mehta N, Wayne AS, Kim YH, Hale GA, Alvarado CS, Myskowski P, Jaffe ES, Busam KJ, Pulitzer M, Zwerner J, Horwitz S. Clin Lymphoma Myeloma Leuk. 2011 Oct 14.
  EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma.
Kempf W, Pfaltz K, Vermeer MH, Cozzio A, Ortiz-Romero PL, Bagot M, Olsen E, Kim YH, Dummer R, Pimpinelli N, Whittaker S, Hodak E, Cerroni L, Berti E, Horwitz S, Prince HM, Guitart J, Estrach T, Sanches JA, Duvic M, Ranki A, Dreno B, Ostheeren-Michaelis S, Knobler R, Wood G, Willemze R. Blood 118:4024-35, 2011
  The Stanford University experience with conventional-dose, total skin electron-beam therapy in the treatment of generalized patch or plaque (T2) and tumor (T3) mycosis fungoides.
Navi D, Riaz N, Levin YS, Sullivan NC, Kim YH, Hoppe RT. Arch Dermatol. 2011; 147 (5): 561-7
  Revisiting low-dose total skin electron beam therapy in mycosis fungoides.
Harrison C, Young J, Navi D, Riaz N, Lingala B, Kim Y, Hoppe R. Int J Radiat Oncol Biol Phys. 2011; 81 (4): e651-7
  Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer.
Olsen EA, Whittaker S, Kim YH, Duvic M, Prince HM, Lessin SR, Wood GS, Willemze R, Demierre MF, Pimpinelli N, Bernengo MG, Ortiz-Romero PL, Bagot M, Estrach T, Guitart J, Knobler R, Sanches JA, Iwatsuki K, Sugaya M, Dummer R, Pittelkow M, Hoppe R, Parker S, Geskin L, Pinter-Brown L, Girardi M, Burg G, Ranki A, Vermeer M, Horwitz S, Heald P, Rosen S, Cerroni L, Dreno B, Vonderheid EC. J Clin Oncol. 2011; 29 (18): 2598-607
  Phase I trial of toll-like receptor 9 agonist, PF-3512676 (CPG7909), in patients with treatment-refractory, cutaneous T-cell lymphoma.
Kim YH
, Girardi M, Duvic M, Kuzel T, Link BK, Pinter-Brown L, Rook AH: J Am Acad Dermatol 63:975-83, 2010
  In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study.
Brody JD, Ai WZ, Czerwinski DK, Torchia JA, Levy M, Advani RH, Kim YH, Hoppe RT, Knox SJ, Shin LK, Wapnir I, Tibshirani RJ, Levy R. J Clin Oncol. 2010; 28 (28): 4324-32
  Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma.
Whittaker SJ, Demierre MF, Kim EJ, Rook AH, Lerner A, Duvic M, Scarisbrick J, Reddy S, Robak T, Becker JC, Samtsov A, McCulloch W, Kim YH. J Clin Oncol. 2010; 28 (29): 4485-91
  Combined use of PCR-based TCRG and TCRB clonality tests on paraffin-embedded skin tissue in the differential diagnosis of mycosis fungoides and inflammatory dermatoses.
Zhang B, Beck AH, Taube JM, Kohler S, Seo K, Zwerner J, Viakhereva N, Sundram U, Kim YH, Schrijver I, Arber DA, Zehnder JL. J Mol Diagn. 2010; 12 (3): 320-7
  Multidisciplinary care in the management of patients with cutaneous lymphoma: a perspective.
Kim YH, Clin Lymphoma Myeloma Leuk. 2010: 10 S106-8

Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma.|
Kim YH, Girardi M, Duvic M, Kuzel T, Link BK, Pinter-Brown L, Rook AH. J Am Acad Dermatol. 2010; 63 (6): 975-83


A phase II study of SGN-30 in cutaneous anaplastic large cell lymphoma and related lymphoproliferative disorders.
Duvic M, Reddy SA, Pinter-Brown L, Korman NJ, Zic J, Kennedy DA, Lorenz J, Sievers EL, Kim YH. Clin Cancer Res. 2009; 15 (19): 6217-24


Cutaneous peripheral T-cell lymphoma associated with a proliferation of B cells.
Mattoch IW, Fulton R, Kim Y, Hoppe R, Warnke RA, Sundram UN. Am J Clin Pathol. 2009; 131 (6): 810-9


Low stage follicular lymphoma: biologic and clinical characterization according to nodal or extranodal primary origin.
Weinberg OK, Ma L, Seo K, Beck AH, Pai RK, Morales A, Kim Y, Sundram U, Tan D, Horning SJ, Hoppe RT, Natkunam Y, Arber DA. Am J Surg Pathol. 2009; 33 (4): 591-8

  Prognostic factors in primary cutaneous anaplastic large cell lymphoma: characterization of clinical subset with worse outcome.
Woo DK, Jones CR, Vanoli-Storz MN, Kohler S, Reddy S, Advani R, Hoppe RT, Kim YH. Arch Dermatol. 2009; 145 (6): 667-74

Clinicopathologic features and treatment outcomes in Woringer-Kolopp disease.
Lee J, Viakhireva N, Cesca C, Lee P, Kohler S, Hoppe RT, Kim YH. J Am Acad Dermatol. 2008; 59 (4): 706-12


Cytologic evaluation of lymphadenopathy associated with mycosis fungoides and Sezary syndrome: role of immunophenotypic and molecular ancillary studies.
Pai RK, Mullins FM, Kim YH, Kong CS. Cancer. 2008; 114 (5): 323-32


Evaluation of B-cell clonality using the BIOMED-2 PCR method effectively distinguishes cutaneous B-cell lymphoma from benign lymphoid infiltrates.
Morales AV, Arber DA, Seo K, Kohler S, Kim YH, Sundram UN. Am J Dermatopathol. 2008; 30 (5): 425-30

  Indolent primary cutaneous B-cell lymphoma: experience using systemic rituximab.
Morales AV, Advani R, Horwitz SM, Riaz N, Reddy S, Hoppe RT, Kim YH. J Am Acad Dermatol. 2008; 59 (6): 953-7

Nephrogenic systemic fibrosis: relationship to gadolinium and response to photopheresis.
Richmond H, Zwerner J, Kim Y, Fiorentino D. Arch Dermatol. 2007; 143 (8): 1025-30

  Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma.
Kim YH, Duvic M, Obitz E, Gniadecki R, Iversen L, Osterborg A, Whittaker S, Illidge TM, Schwarz T, Kaufmann R, Cooper K, Knudsen KM, Lisby S, Baadsgaard O, Knox SJ. Blood. 2007; 109 (11): 4655-62
  TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC).
Kim YH, Willemze R, Pimpinelli N, Whittaker S, Olsen EA, Ranki A, Dummer R, Hoppe RT. Blood. 2007; 110 (2): 479-84

Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.
Olsen EA, Kim YH, Kuzel TM, Pacheco TR, Foss FM, Parker S, Frankel SR, Chen C, Ricker JL, Arduino JM, Duvic M. J Clin Oncol. 2007; 25 (21): 3109-15


Second lymphomas and other malignant neoplasms in patients with mycosis fungoides and Sezary syndrome: evidence from population-based and clinical cohorts.
Huang KP, Weinstock MA, Clarke CA, McMillan A, Hoppe RT, Kim YH. Arch Dermatol. 2007; 143 (1): 45-50


T-cell clonality analysis in biopsy specimens from two different skin sites shows high specificity in the diagnosis of patients with suggested mycosis fungoides.
Thurber SE, Zhang B, Kim YH, Schrijver I, Zehnder J, Kohler S. J Am Acad Dermatol. 2007; 57 (5): 782-90


Cutaneous involvement by angioimmunoblastic T-cell lymphoma: a unique histologic presentation, mimicking an infectious etiology.
Jayaraman AG, Cassarino D, Advani R, Kim YH, Tsai E, Kohler S. J Cutan Pathol. 2006: 33 Suppl 2 6-11


Staging accuracy in mycosis fungoides and sezary syndrome using integrated positron emission tomography and computed tomography.
Tsai EY, Taur A, Espinosa L, Quon A, Johnson D, Dick S, Chow S, Advani R, Warnke R, Kohler S, Hoppe RT, Kim YH. Arch Dermatol. 2006; 142 (5): 577-84



Footer Links: